Geode Capital Management
RLMD icon

Geode Capital Management’s Relmada Therapeutics RLMD Stock Holding History

Geode Capital Management’s Portfolio RLMD Stock Details RLMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$17.3M Buy
2,492,573
+1,643,890
+194% +$11.5M ﹤0.01% 2238
2026
Q1 		$5.91M Sell
848,683
-6,249
-0.7% -$29.6K ﹤0.01% 2661
2025
Q4 		$4.13M Buy
854,932
+558,717
+189% +$1.87M ﹤0.01% 2874
2025
Q3 		$596K Sell
296,215
-6,139
-2% -$5.89K ﹤0.01% 3552
2025
Q2 		$182K Buy
302,354
+471
+0.2% +$242 ﹤0.01% 3905
2025
Q1 		$81.5K Sell
301,883
-955
-0.3% -$317 ﹤0.01% 4086
2024
Q4 		$158K Sell
302,838
-1,664
-0.5% -$4.06K ﹤0.01% 3969
2024
Q3 		$987K Buy
304,502
+44,004
+17% +$143K ﹤0.01% 3359
2024
Q2 		$782K Buy
260,498
+4,411
+2% +$16K ﹤0.01% 3401
2024
Q1 		$1.19M Buy
256,087
+12,674
+5% +$61.1K ﹤0.01% 3300
2023
Q4 		$1.01M Buy
243,413
+3,509
+1% +$10.4K ﹤0.01% 3354
2023
Q3 		$720K Buy
239,904
+5,542
+2% +$16.5K ﹤0.01% 3458
2023
Q2 		$577K Sell
234,362
-267,981
-53% -$741K ﹤0.01% 3588
2023
Q1 		$1.14M Buy
502,343
+16,092
+3% +$55.5K ﹤0.01% 3287
2022
Q4 		$1.7M Sell
486,251
-4,561
-0.9% -$40.1K ﹤0.01% 3113
2022
Q3 		$18.2M Sell
490,812
-6,515
-1% -$180K ﹤0.01% 1807
2022
Q2 		$9.44M Buy
497,327
+42,423
+9% +$925K ﹤0.01% 2292
2022
Q1 		$12.3M Buy
454,904
+110,947
+32% +$2.29M ﹤0.01% 2210
2021
Q4 		$7.75M Buy
343,957
+90,254
+36% +$2.01M ﹤0.01% 2625
2021
Q3 		$6.65M Buy
253,703
+9,371
+4% +$251K ﹤0.01% 2744
2021
Q2 		$7.82M Buy
244,332
+5,060
+2% +$176K ﹤0.01% 2633
2021
Q1 		$8.42M Buy
239,272
+33,585
+16% +$1.17M ﹤0.01% 2470
2020
Q4 		$6.6M Buy
205,687
+5,437
+3% +$187K ﹤0.01% 2435
2020
Q3 		$7.53M Buy
200,250
+2,007
+1% +$77.6K ﹤0.01% 2139
2020
Q2 		$8.87M Buy
198,243
+90,554
+84% +$3.83M ﹤0.01% 1990
2020
Q1 		$3.67M Buy
107,689
+10,581
+11% +$427K ﹤0.01% 2321
2019
Q4 		$3.79M Buy
+97,108
New +$2.95M ﹤0.01% 2615

Other funds holding RLMD

JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $322M AUM
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
SSC
Spruce Street Capital New York $510M AUM
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JHC
Jones Hill Capital New York $470M AUM
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management's RLMD Position: Q2 2026 in Review

Geode Capital Management increased its Relmada Therapeutics (RLMD) stake by 194% in Q2 2026, buying an estimated $11.5M and bringing the position to 2,492,573 shares worth $17.3M. The position accounts for ﹤0.01% of the portfolio, ranked #2238.

Geode Capital Management first reported a position in RLMD in Q4 2019 and has held it in 27 quarters since. The position peaked at $18.2M in Q3 2022. 126 funds tracked by Wall St. Rank hold RLMD as of Q2 2026.

  • Geode Capital Management held 2,492,573 shares of Relmada Therapeutics worth $17.3M as of Q2 2026.
  • Geode Capital Management bought 1,643,890 Relmada Therapeutics shares in Q2 2026, an estimated $11.5M.
  • Relmada Therapeutics made up ﹤0.01% of Geode Capital Management's portfolio in Q2 2026, its #2238 holding.
  • Geode Capital Management first reported a position in Relmada Therapeutics in Q4 2019 and has held it in 27 quarters since.
  • Geode Capital Management's Relmada Therapeutics position peaked at $18.2M in Q3 2022.
  • 126 funds tracked by Wall St. Rank held Relmada Therapeutics as of Q2 2026.

Based on Geode Capital Management's 13F filing for Q2 2026, filed 12 Aug 2026.